eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
Portal dla gastroenterologów!
SCImago Journal & Country Rank
vol. 13
Poleć ten artykuł:
streszczenie artykułu:
Artykuł oryginalny

Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection

Paulina Konrad, Jan Chojnacki, Anita Gąsiorowska, Cezary Rudnicki, Aleksandra Kaczka, Cezary Chojnacki

Data publikacji online: 2018/03/12
Pełna treść artykułu
Pobierz cytowanie
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero

Small intestinal bacterial overgrowth (SIBO) may coexist with Helicobacter pylori infection, which can be the cause of chronic gastrointestinal complaints.

Evaluation of the therapeutic efficacy of amoxicillin and rifaximin in the treatment of these diseases.

Material and methods
The lactulose hydrogen breath test (LHBT) and the urea breath test (13C-UBT) were performed in 116 patients. In 62 patients the coexistence of small intestinal bacterial overgrowth and H. pylori infection was observed. Then, in group I (n = 30) pantoprazole (2 × 40 mg), amoxicillin (2 × 1000 mg) and metronidazole (2 × 500 mg) and in group II (n = 32) pantoprazole and amoxicillin at the above doses and rifaximin (3 × 400 mg) were administered for 10 days. After 6 weeks, both breath tests were repeated and the degree of remission of symptoms was measured using a 10-point visual analog scale (VAS).

After the treatment the LHBT index decreased in group I from 61.2 ±19.4 ppm to 22.0 ±8.2 ppm (p < 0.001) and in group II from 59.6 ±15.5 ppm to 15.2 ±8.6 ppm (p < 0.001). Eradication of H. pylori (13C-UBT below 4.0‰) was achieved in 63.3% of patients in group I and 59.4% in group II (p > 0.05). The decrease of pain below 3.0 points in the VAS was obtained in 64.8% of patients in group I and in 56.2% in group II.

Combination of amoxicillin and rifaximin may be effective in the treatment of patients with small intestinal bacterial overgrowth syndrome and concomitant H. pylori infection.

Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010; 8: 504-8.
Marlicz W, Loniewski I, Grimes DS, Quigley EM. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc 2014; 89: 1699-709.
Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol 2015; 21: 6817-9.
Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011; 41: 380-6.
Osawa H, Kita H, Ohnishi H, et al. Changes in plasma ghrelin levels, gastric ghrelin production, and body weight after Helicobacter pylori cure. J Gastroenterol 2006; 41: 954-61.
Jang EJ, Park SW, Park JS, et al. The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. J Gastroenterol Hepatol 2008; 23 Suppl 2: 278-85.
Ulasoglu C, Isbilen B, Doganay L, et al. Effect of Helicobacter pylori eradication on serum ghrelin and obestatin levels. World J Gastroenterol 2013; 19: 2388-94.
Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J 2010; 103: 190-6.
Albaker WL. Helicobacter pylori infection and its relatonship to metabolic syndrome: is it a myth or fact? Saudi J Gastroenterol 2011; 17: 165-9.
Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients 2014; 6: 5583-99.
Schwiertz A, Taras D, Schäfer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2010; 18: 190-5.
Stachowicz N, Kiersztan A. The role of gut microbiota in the pathogenesis of obesity and diabetes. Postepy Hig Med Dosw 2013; 67: 288-303.
Sugano K, Tack J, Kuipers EJ, et al. Faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353-67.
Bayeli PF, Mariottini M, Lisi L, et al. Guidelines on intestinal dysmicrobism (SIBO Small Intestine Bacterial Overgrowth). Minerva Gastroenterol Dietol 1999; 45: 297-308.
Gasbarrini A, Lauritano EC, Gabrielli M, et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 2007; 25: 237-40.
Enko D, Kriegshäuser G. Functional 13C-urea and glucose hydrogen/methane breath tests reveal significant association of small intestinal bacterial overgrowth in individuals with active Helicobacter pylori infection. Clin Biochem 2017; 50: 46-9.
Schulz C, Koch N, Schütte K, et al. H. pylori and its modulation of gastrointestinal microbiota. J Dig Dis 2015; 16: 109-17.
Llorca L, Pérez-Pérez G, Urruzuno P, et al. Characterization of the gastric microbiota in a pediatric population according to Helicobacter pylori status. Pediatr Infect Dis J 2017; 36: 173-8.
Sheh A, Fox JG. The role of the gastrointestinal microbiome in Helicobacter pylori pathogenesis. Gut Microbes 2013; 4: 505-31.
Lauritano EC, Gabrielli M, Scarpellini E, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009; 13: 111-6.
Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017; 45: 604-16.
Mégraud F, Bouffant F, Camou Juncas C. In vitro activity of rifaximin against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1994; 13: 184-6.
Sunny J Jr, Garcia CJ, McCallum RW. Interpreting the lactulose breath test for the diagnosis of small intestinal bacterial overgrowth. Am J Med Sci 2016; 351: 229-32.
Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2013; 38: 925-34.
Di Stefano M, Miceli E, Missanelli A, et al. Absorbable vs. non-absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind-loop syndrome. Aliment Pharmacol Ther 2005; 21: 985-92.
Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs 2009; 18: 349-58.
Holton J, Vaira D, Menegatti M, Barbara L. The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J Antimicrob Chemother 1995; 35: 545-9.
De Giorgio R, Stanghellini V, Barbara G, et al. Rifaximin and Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci 1997; 1: 105-10.
Quesada M, Sanfeliu I, Junquera F, et al. [Evaluation of Helicobacter pylori susceptibility to rifaximin]. Gastroenterol Hepatol 2004; 27: 393-6.
Gasbarrini A, Gasbarrini G, Pelosini I, Scarpignato C. Eradication of Helicobacter pylori: are rifaximin-based regimens effective? Digestion 2006; 73 Suppl 1: 129-35.
Nizhevich AA, Shcherbakov PL, Akhmadeeva ÉN, Khasanov RS. Rifaximin in combined treatment of the Helicobacter pylori infection in childhood. Eksp Klin Gastroenterol 2011; 1: 85-7.
Yun SP, Seon HG, Ok CS, et al. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver 2012; 6: 452-6.
Choi KH, Chung WC, Lee KM, et al. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011; 26: 785-90.
Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol 2014; 20: 1517-28.
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe